{
    "paper_id": "PMC7162064",
    "metadata": {
        "title": "High fractional exhaled nitric oxide and sputum eosinophils are associated with an increased risk of future virus\u2010induced exacerbations: A prospective cohort study",
        "authors": [
            {
                "first": "A.",
                "middle": [],
                "last": "Bjerregaard",
                "suffix": "",
                "email": "asger.bjerregaard@dadlnet.dk",
                "affiliation": {}
            },
            {
                "first": "I.",
                "middle": [
                    "A."
                ],
                "last": "Laing",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "V.",
                "middle": [],
                "last": "Backer",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "A.",
                "middle": [],
                "last": "Sverrild",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "S.\u2010K.",
                "middle": [],
                "last": "Khoo",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "G.",
                "middle": [],
                "last": "Chidlow",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "C.",
                "middle": [],
                "last": "Sikazwe",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "D.",
                "middle": [
                    "W."
                ],
                "last": "Smith",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "P.",
                "middle": [],
                "last": "Le Sou\u00ebf",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "C.",
                "middle": [],
                "last": "Porsbjerg",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "Asthma is an inflammatory disease of the airways characterised by variable airflow obstruction and hyperresponsiveness and is one of the most frequent chronic diseases of young adults. Acute exacerbations are the main cause of morbidity and healthcare utilisation1 and thus preventing future exacerbations is a key goal in the clinical management of patients with asthma.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Infection with respiratory viruses, particularly rhinoviruses (RV), is a common trigger of asthma exacerbations, but the mechanisms are still unclear.2, 3, 4 Airway epithelial cells cultured ex vivo from non\u2010asthmatic subjects produce TSLP, IL\u201025 and IL\u201033 in response to viral infection, and more so in asthmatic individuals.5, 6, 7 These \u201calarmins\u201d stimulate T helper cells and innate lymphoid cells to produce IL\u20104, IL\u20105 and IL\u201013,8, 9 which causes recruitment of eosinophils to the airways, increased mucus secretion, bronchial hyperreactivity and class switching by B\u2010cells to produce IgE.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Whether IL\u20105\u2010mediated eosinophilic inflammation is also a risk factor for virus\u2010induced exacerbations is unknown, but it has been demonstrated that viruses can activate eosinophils, both directly10 and by signalling through toll like receptors (such as TLR3 and TLR7) resulting in further propagation of inflammation.11 Anti\u2010Il\u20105 reduces the rate of exacerbations, but whether this effect is predominantly related to virus induced, or non\u2010viral exacerbations, is unknown.12\n",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Adjusting inhaled corticosteroid (ICS) treatment based on maintaining low airway eosinophils is more effective than symptom based management in reducing exacerbation frequency,13, 14 but induction and processing of sputum are not feasible in most clinical settings. Fractional exhaled nitric oxide (FeNO) is produced by airway epithelial cells on stimulation with IL\u20104 and IL\u201013 and has been associated with increased risk of exacerbation,15 but treatment strategies based on FeNO to reduce the rate of exacerbations have showed conflicting results.16, 17, 18, 19 Trials of anti\u2010IL\u201013 antibodies have shown a reduction in exacerbation rates in patients with high periostin (protein induced by IL\u201013), who were receiving treatment with ICS and had poor asthma control.20 To our knowledge, no study has evaluated the association between FeNO or sputum eosinophils and the risk of virus\u2010induced exacerbations specifically.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "We hypothesised that high type 2 inflammatory biomarkers would be associated with a higher risk of virus\u2010induced asthma exacerbations. To test this, we conducted an observational, prospective cohort study of at heterogeneous population of asthmatics, examining patients at baseline and subsequently during exacerbation.",
            "cite_spans": [],
            "section": "Introduction",
            "ref_spans": []
        },
        {
            "text": "Stable asthma patients were recruited in the period of May 2013 to December 2014 from a respiratory outpatient clinic at Bispebjerg University Hospital in Copenhagen, Denmark. Patients had all been followed for at least 12 months in the specialist outpatient clinic, before enrolment into this study.",
            "cite_spans": [],
            "section": "Study design ::: Methods",
            "ref_spans": []
        },
        {
            "text": "Patients were examined as described below and then followed for 18 months from the entry date, during which time patients were instructed to contact the study team, if they experienced any worsening of their asthma symptoms or an increase in beta2\u2010agonist use, surpassing their usual day\u2010to\u2010day variation. Patients were examined within 24 hours of contact with the study team. Exacerbations were defined as increased symptoms that required a change in medication as judged by the attending physician, in line with ATS/ERS recommendations.21 Exacerbations managed by adjusting inhaled therapies were recorded as mild/moderate, whereas exacerbations requiring a course of oral corticosteroids (OCS) or admission to hospital, were considered severe.21 In addition, patients were instructed to perform a nasal swab at home, when experiencing symptoms of a common cold\u2014patients were not examined further on this occasion. The local scientific ethics committee approved the study (journal nr: H\u20103\u20102011\u2010121). All subjects were informed and gave written consent.",
            "cite_spans": [],
            "section": "Study design ::: Methods",
            "ref_spans": []
        },
        {
            "text": "Spirometry (EasyOne, NDD, Switzerland) was completed according to ERS recommendations,22 using NHANES III as the reference.23 A skin prick test (Soluprick, ALK, Denmark) was completed, and atopy was defined as a positive test (maximum wheal diameter \u22653 mm) to at least one of ten common aeroallergens (grasses, house dust mite, birch, mugwort, dog, cat, horse, cladosporum herbarum and alternaria tenuis). Fractional expiratory nitric oxide (FeNO) was analysed on a NioxMinor (Aerocrine, Solna, Sweden) following the recommendations of the ERS and ATS24 using the mean of two measurements. The ATS\u2010defined cut\u2010off of 25 ppb of FeNO was used to define patients with high and low FeNO. Sputum was induced according to the ERS guidelines and processed using a protocol described by Pavord et al.25 Differential cell counts from cytospins were obtained from 400 non\u2010squamous cells. A cut\u2010off of 1% for sputum eosinophils was applied to define those with high and low sputum eosinophils, as it has been reported to correspond to the 95th percentile of sputum eosinophils in healthy adults.26\n",
            "cite_spans": [],
            "section": "Assessments ::: Methods",
            "ref_spans": []
        },
        {
            "text": "Blood samples were assessed by the hospital clinical service and included a full white blood cell differential count and measurement of C\u2010reactive protein (CRP) as well as total IgE (Cobas 8000; Roche, Basel, Switzerland). Asthma control was assessed with the Asthma Control Questionnaire (ACQ).27\n",
            "cite_spans": [],
            "section": "Assessments ::: Methods",
            "ref_spans": []
        },
        {
            "text": "Nasal swabs (Copan Italia) were used to sample nasal fluid and tested using a tandem multiplex real\u2010time PCR assay detecting a comprehensive range of respiratory viruses: Human adenovirus species B\u2010D; human bocavirus; coronaviruses OC43, 229E, HKU1 and NL63; influenza viruses A, B and C; parainfluenza viruses 1\u20104; KI and WU polyomaviruses; respiratory syncytial virus types A and B and human metapneumovirus.28, 29 RV was detected by a PCR directed at sequences in the 5\u2032UTR genome of RV, and the products were identified to species level as RV\u2010A, RV\u2010B or RV\u2010C by sequencing of this 260 bp product and alignment to known RV sequences using ClustalX software.30, 31 Bispebjerg hospital laboratory completed bacterial cultures on spontaneous expectorates gathered at exacerbation.",
            "cite_spans": [],
            "section": "Detection of respiratory pathogens ::: Methods",
            "ref_spans": []
        },
        {
            "text": "The data were analysed with SPSS version 22.0 (IBM SPSS, Armonk, NY, USA). Normally distributed data are reported as mean\u00b1standard deviation and analysed using student's t test for continuous variables, and chi\u2010squared test for categorical variables. Log\u2010transformed variables are reported as geometric mean (GM) with 95% CI. Non\u2010normally distributed data (eg, cell counts) are reported as median (range), and comparisons were made using Kruskal\u2010Wallis test.",
            "cite_spans": [],
            "section": "Statistical analyses ::: Methods",
            "ref_spans": []
        },
        {
            "text": "To assess the ability of baseline characteristics to predict risk of exacerbation, a proportional hazards model (Cox regression) was used and adjusted for predefined potential confounders of exacerbation risk, including ICS dose, smoking status, ACQ score and % predicted FEV1 (forced expiratory volume in the first second of expiration) at baseline. As the inflammatory markers examined (FeNO, sputum eosinophils) are highly correlated (both in previous studies and in our data), each marker was tested separately in to avoid multicollinearity. For all analyses a P\u2010value of <.05 was considered significant.",
            "cite_spans": [],
            "section": "Statistical analyses ::: Methods",
            "ref_spans": []
        },
        {
            "text": "A total of 112 patients were approached, of which 81 patients agreed to participate (Figure 1). ICS were taken by 73% of patients, with the remaining 27% using short acting beta2\u2010agonists alone. In 18 of the 81 recruited patients (22%), FeNO was elevated at baseline (>25 ppb), and among the 56 patients able to produce a valid sputum sample, 16 patients (20%) had sputum eosinophils >1%. Eight patients had both high FeNO and high sputum eosinophils. The clinical characteristics of study subjects are described in Table 1.",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 92,
                    "end": 93,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 522,
                    "end": 523,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "During the follow\u2010up period, 22 participants (27%) developed an exacerbation (Figure 1). No patients had more than one exacerbation during the study period. In 15 of 22 patients with an exacerbation (68%), a respiratory virus was detected at exacerbation, predominantly RV and human coronavirus (HCoV) (Figure 2). A course of oral corticosteroid was prescribed for 36% of patients with an exacerbation, whereas the remaining 64% were managed with a temporary increase in ICS alone. No patients required admission to hospital. Two patients were treated with antibiotics for suspected bacterial pneumonia, although bacterial cultures were later found to be negative.",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 85,
                    "end": 86,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                },
                {
                    "start": 310,
                    "end": 311,
                    "mention": "2",
                    "ref_id": "FIGREF1"
                }
            ]
        },
        {
            "text": "Patient characteristics, including age, sex and smoking status, were not different between those that had an exacerbation and those who did not (Table 1). In the exacerbation group, mean FeNO at baseline was higher (24 ppb 95% CI: 17\u201033, P=.048) compared to the non\u2010exacerbation group (18 ppb 95% CI: 16\u201020). Exacerbation patients also had a higher ACQ score at baseline (1.4\u00b11.1, P=.011) compared to the non\u2010exacerbation patients (0.8\u00b10.9). There was a trend for lower prevalence of atopy in the exacerbation group (46% vs 68%, P=.066). Lung function, ICS dose and both sputum and blood differential cell counts were similar between the groups (Table 1).",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 151,
                    "end": 152,
                    "mention": "1",
                    "ref_id": "TABREF0"
                },
                {
                    "start": 652,
                    "end": 653,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "In patients with high sputum eosinophils at baseline, five patients (29%) had a virus\u2010positive exacerbation, compared to the eosinophil low group that had six patients (12%) with a virus\u2010positive exacerbation (P=.10). Among patients with high FeNO at baseline, six patients (27%) experienced a virus\u2010positive exacerbation, compared to the FeNO low group that had nine patients (12%) with a virus\u2010positive exacerbation (P=.05).",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": []
        },
        {
            "text": "Unadjusted log\u2010rank tests showed that patients with high FeNO had a shorter time to exacerbation than those with low FeNO (381 days [95% CI: 292\u2010470] vs 479 days [95% CI: 445\u2010513], P=.01), and specifically a shorter time to a virus\u2010induced exacerbation (410 days [95% CI: 319\u2010502] vs 500 days [95% CI: 471\u2010529], P=.04), respectively. A similar difference in time to any exacerbation was seen when comparing patients based on higher vs lower ACQ score. Patients with an ACQ score >1.5 had 392 days (95% CI: 318\u2010467, P=.01) to their exacerbation vs 480 days (95% CI: 443\u2010516) for those with an ACQ score \u22641.5. However, there was no difference in time to virus\u2010induced exacerbation for those with a high vs low ACQ score (447 days [95% CI: 379\u2010514] vs 490 days [95% CI: 455\u2010526], P=.12), respectively. In these unadjusted analyses, patients with or without sputum eosinophilia had similar time to exacerbation (P=.26; Figure 3).",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 922,
                    "end": 923,
                    "mention": "3",
                    "ref_id": "FIGREF2"
                }
            ]
        },
        {
            "text": "Proportional hazards models were constructed adjusting for known determinants of exacerbation risk (amount of ICS usage, current smoking, ACQ score and % predicted FEV1) at baseline. All demographic variables (sex, age, BMI) had a P\u2010value >.3 in univariate analyses and were not included in the models. Each inflammatory marker was assessed separately for predicting risk of exacerbation (summarised in Table 2). There were too few patients in the virus\u2010negative group for this analysis.",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 409,
                    "end": 410,
                    "mention": "2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "High FeNO at baseline increased the risk of any subsequent exacerbation (HR 3.1 [95% CI: 1.2\u20107.8], P=.015) and increased the risk of virus\u2010positive exacerbations (HR 3.4 [95% CI: 1.1\u201010.4], P=.033) compared to those with low FeNO. High sputum eosinophils also increased the risk of any exacerbation (HR 4.1 [95% CI: 1.2\u201013.8], P=.024), and particularly virus\u2010positive exacerbations (HR 7.6 [95% CI: 1.6\u201035.2], P=.010) compared to those with low eosinophils (Table 2). In other words, patients with FeNO >25 ppb had a 3.4\u2010fold increased risk of virus\u2010induced exacerbation compared to patients with lower FeNO, and patients with sputum eosinophils >1% had a 7.6\u2010fold increased risk, compared to patients with lower eosinophil percentage when disease control, lung function, ICS use and tobacco consumption at baseline were kept the same.",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 464,
                    "end": 465,
                    "mention": "2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "Other potentially relevant risk factors relating to type 2 inflammation were also examined with adjustment for the same potential confounders as above: Atopic status, blood eosinophils >150\u00d7109 cells/L and total IgE >150\u00d7103 IU. None of these variables predicted the risk of exacerbation (Table 2).",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 295,
                    "end": 296,
                    "mention": "2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "A total of 21 patients sent in a swab during symptoms of a common cold, without any signs of an exacerbation. Of these 11 (52%) had a detectable respiratory virus (5 RV\u2010A, 1 RV\u2010B, 4 RV\u2010C and 1 enterovirus). Sputum eosinophils and mean FeNO at baseline were not different between those with no exacerbation or cold (n=38), those who experienced a virus\u2010positive cold (n=11) and those with a virus\u2010positive exacerbation (n=15; Table 3). However, the proportion of patients with FeNO >25 was significantly different, and lowest in those with a virus\u2010positive cold and highest in those with a virus\u2010positive exacerbation (Table 3). Patients with a virus\u2010positive exacerbation did not have a higher FeNO at exacerbation (GM 22 ppb 95% CI: 15\u201032) than a follow\u2010up (GM 22 ppb 95% CI: 13\u201035, .905).",
            "cite_spans": [],
            "section": "Results",
            "ref_spans": [
                {
                    "start": 431,
                    "end": 432,
                    "mention": "3",
                    "ref_id": "TABREF2"
                },
                {
                    "start": 624,
                    "end": 625,
                    "mention": "3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "In this study, both FeNO >25 ppb and sputum eosinophils >1% were associated with an increased risk of developing a virus\u2010induced asthma exacerbation. Furthermore, patients who developed a virus\u2010induced exacerbation were more likely to have FeNO >25 ppb at baseline, than patients who only reported upper respiratory symptoms during respiratory viral infection. While both FeNO and sputum eosinophils have been associated with a higher risk of exacerbation in general,13, 14, 15 to our knowledge, this is the first study to assess type 2 airway inflammation as a risk factor specifically for virus\u2010induced asthma exacerbations.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "The rate of exacerbation was lower than previous studies with a similar design, and because the majority of exacerbations were virus induced, there were too few patients with non\u2010viral exacerbations to rule out an association between type 2 inflammation at baseline and risk of exacerbation in this group. Indeed, given that there was a similar proportion of virus\u2010positive vs virus\u2010negative exacerbations in both the low and high group of each type 2 marker, it seems plausible that the effect is not limited to virus\u2010induced exacerbations. Nevertheless, we have identified an association between type 2 inflammation and virus\u2010induced exacerbations, suggesting this area warrants further investigation.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Other limitations include a lack of surveillance of patients (eg, peak flow monitoring), hence registration of exacerbations was depended on the patients contacting the research unit when they experienced symptoms surpassing their daily variation. However, patients were regularly contacted by phone to remind them of their participation in the study. Finally, it is possible the results might be different in a cohort of more severe asthmatics, with a higher exacerbation rate and potentially more severe exacerbations. The strength of this study is that it prospectively followed a heterogeneous population of asthmatics, representative of the everyday clinical scenario experienced by most respiratory clinicians.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "A causal role of type 2 inflammation in asthma exacerbations has been supported by studies of antibodies inhibiting IL\u20105 and IL\u201013 signalling. Phase II and III studies of the monoclonal anti\u2010IL\u20105 antibody mepolizumab have shown a reduction in exacerbation frequency by approximately half32, 33\u2014an effect that was lost within 6 months of treatment cessation.34 Likewise, treatment with the anti\u2010IL\u201013 antibody Lebrikizumab, reduced the rate of exacerbations by 60% in moderate to severe asthmatics with elevated periostin.20 Whether the exacerbations that can be prevented with these strategies are predominantly viral or non\u2010viral have yet to be reported, but our data suggests that an effect on virus\u2010induced exacerbations is likely.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "None of the participants who only developed upper respiratory tract symptoms had FeNO above 25 ppb, while 40% of those who developed an exacerbation had elevated FeNO. This is in line with our finding that high FeNO increased the risk of virus\u2010induced exacerbation, and suggests that patients with well\u2010controlled type 2 inflammation are more resistant to lower airways involvement when infected with common respiratory viruses. However, for this exploratory outcome the numbers were low, and FeNO levels were not different when analysed as a continuous variable and therefore this needs further exploration in larger studies.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "A synergistic effect of allergic sensitisation and viral infection on risk of hospital admission has been described in children.35 In our study, we did not observe an increased risk of exacerbation (viral or non\u2010viral) in patients sensitised to common aeroallergens, indicating that this association might be more pronounced in paediatric populations.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "Studies have found that cross\u2010linking of the high affinity IgE\u2010receptor (Fc\u03b5R1) results in blunted interferon responses to RV,36, 37 which in turn is associated with ineffective viral clearing38 and more pronounced asthma symptoms.39, 40 Furthermore, the anti\u2010IgE antibody omalizumab has been shown to eliminate the return\u2010to\u2010school peaks of exacerbations in a large cohort of asthmatic children, suggestive of a reduction of virus\u2010induced exacerbations.12 Taken together this indicates that high IgE might play a role in virus\u2010induced asthma exacerbations; however, in our study, high IgE was not associated with an increased risk of virus\u2010induced exacerbations.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "With the advent of further antibody treatment options in the coming years, there is a widespread intent to enhance personalised asthma management, by tailoring medication choice and dosage according to the inflammatory phenotype. These treatments are likely to prevent some, but not all, exacerbations. Given that respiratory viruses are a major trigger of exacerbations, understanding how each pathway of airway inflammation influences the risk of virus\u2010induced exacerbation will be a critical step in understanding how to optimise the use of antibody therapies to achieve the best individual patient outcomes.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "In conclusion, we have shown that high FeNO and sputum eosinophils at baseline are risk factors for virus\u2010induced exacerbations in a real\u2010life setting. If confirmed in larger studies, this could have implications on the risk assessment of asthma patients.",
            "cite_spans": [],
            "section": "Discussion",
            "ref_spans": []
        },
        {
            "text": "The authors declare no conflict of interest.",
            "cite_spans": [],
            "section": "Conflicts of interest",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Baseline characteristics of patients who developed an exacerbation during follow\u2010up (n=22) and those who did not experience any exacerbations (n=59)\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: Proportional hazards models of inflammatory markers at baseline and risk (hazard ratio, HR) of exacerbation (all exacerbations, and virus\u2010induced exacerbations)\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 3: Baseline FeNO and sputum eosinophils in patients with either: (i) no cold symptoms or exacerbation during the study, (ii) only a cold during the study or (iii) an exacerbation during the study\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: \nSTROBE\u2010chart of patients in the study",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure 2: Respiratory viruses detected at exacerbation",
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Figure 3: Log\u2010rank test of time to exacerbation in groups based on FeNO (A), sputum eosinophils (B), ACQ score (C) and blood eosinophils (D)",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention",
            "authors": [],
            "year": 2015,
            "venue": "",
            "volume": "",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Frequency, severity, and duration of rhinovirus infections in asthmatic and non\u2010asthmatic individuals: a longitudinal cohort study",
            "authors": [],
            "year": 2002,
            "venue": "Lancet",
            "volume": "359",
            "issn": "",
            "pages": "831-834",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Respiratory viruses and exacerbations of asthma in adults",
            "authors": [],
            "year": 1993,
            "venue": "BMJ",
            "volume": "307",
            "issn": "",
            "pages": "982-986",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Rhinovirus\u2010induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL\u201010 production",
            "authors": [],
            "year": 2008,
            "venue": "Proc Natl Acad Sci USA",
            "volume": "105",
            "issn": "",
            "pages": "13562-13567",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "Thymic stromal lymphopoietin is induced by respiratory syncytial virus\u2010infected airway epithelial cells and promotes a type 2 response to infection",
            "authors": [],
            "year": 2012,
            "venue": "J Allergy Clin Immunol.",
            "volume": "130",
            "issn": "",
            "pages": "1187-1196",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "NK cell\u00a0deficiency predisposes to viral\u2010induced Th2\u2010type allergic inflammation via epithelial\u2010derived IL\u201025",
            "authors": [],
            "year": 2010,
            "venue": "J Immunol.",
            "volume": "185",
            "issn": "",
            "pages": "4681-4690",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "IL\u201033\u2010dependent type 2 inflammation during rhinovirus\u2010induced asthma exacerbations in\u00a0vivo",
            "authors": [],
            "year": 2014,
            "venue": "Am J Respir Crit Care Med",
            "volume": "190",
            "issn": "",
            "pages": "1373-1382",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "The interleukin\u201033 receptor ST2 is important for the development of peripheral airway hyperresponsiveness and inflammation in a house dust mite mouse model of asthma",
            "authors": [],
            "year": 2016,
            "venue": "Clin Exp Allergy",
            "volume": "46",
            "issn": "",
            "pages": "479-490",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "IL\u201033 and thymic stromal lymphopoietin mediate immune pathology in response to chronic airborne allergen exposure",
            "authors": [],
            "year": 2014,
            "venue": "J Immunol.",
            "volume": "193",
            "issn": "",
            "pages": "1549-1559",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Virus\u2010induced eosinophil mediator release requires antigen\u2010presenting and CD4+ T cells",
            "authors": [],
            "year": 2008,
            "venue": "J Allergy Clin Immunol.",
            "volume": "122",
            "issn": "",
            "pages": "69-77",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Role of atopic status in Toll\u2010like receptor (TLR)7\u2010 and TLR9\u2010mediated activation of human eosinophils",
            "authors": [],
            "year": 2009,
            "venue": "J Leukocyte Biol.",
            "volume": "85",
            "issn": "",
            "pages": "719-727",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Randomized Trial of Omalizumab (Anti\u2010IgE) for Asthma in Inner\u2010City Children",
            "authors": [],
            "year": 2011,
            "venue": "N Engl J\u00a0Med",
            "volume": "364",
            "issn": "",
            "pages": "1005-1015",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial",
            "authors": [],
            "year": 2002,
            "venue": "The Lancet",
            "volume": "360",
            "issn": "",
            "pages": "1715-1721",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations",
            "authors": [],
            "year": 2006,
            "venue": "Eur Respir J",
            "volume": "27",
            "issn": "",
            "pages": "483-494",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Elevated exhaled nitric oxide is a clinical indicator of future uncontrolled asthma in asthmatic patients on inhaled corticosteroids",
            "authors": [],
            "year": 2011,
            "venue": "J Allergy Clin Immunol",
            "volume": "128",
            "issn": "",
            "pages": "412-414",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Symptom\u2010 and fraction of exhaled nitric oxide\u2010driven strategies for asthma control: a cluster\u2010randomized trial in primary care",
            "authors": [],
            "year": 2015,
            "venue": "J Allergy Clin Immunol.",
            "volume": "135",
            "issn": "",
            "pages": "682-688",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Frequent exacerbators\u2013a distinct phenotype of severe asthma",
            "authors": [],
            "year": 2014,
            "venue": "Clin Exp Allergy",
            "volume": "44",
            "issn": "",
            "pages": "212-221",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Comparison of physician\u2010, biomarker\u2010, and symptom\u2010based strategies for adjustment of inhaled corticosteroid therapy in adults with asthma: the BASALT randomized controlled trial",
            "authors": [],
            "year": 2012,
            "venue": "JAMA",
            "volume": "308",
            "issn": "",
            "pages": "987-997",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Anti\u2010inflammatory treatment of atopic asthma guided by exhaled nitric oxide: a randomized, controlled trial",
            "authors": [],
            "year": 2013,
            "venue": "J Allergy Clin Immunol Pract.",
            "volume": "1",
            "issn": "",
            "pages": "639-648",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "Lebrikizumab in moderate\u2010to\u2010severe asthma: pooled data from two randomised placebo\u2010controlled\u00a0studies",
            "authors": [],
            "year": 2015,
            "venue": "Thorax",
            "volume": "70",
            "issn": "",
            "pages": "1-9",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice",
            "authors": [],
            "year": 2009,
            "venue": "Am J Respir Crit Care Med",
            "volume": "180",
            "issn": "",
            "pages": "59-99",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Standardisation of spirometry",
            "authors": [],
            "year": 2005,
            "venue": "Eur Respir J",
            "volume": "26",
            "issn": "",
            "pages": "319-338",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Spirometric reference values from a sample of the general US population",
            "authors": [],
            "year": 1999,
            "venue": "Am J Respir Crit Care Med",
            "volume": "159",
            "issn": "",
            "pages": "179-187",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005",
            "authors": [],
            "year": 2005,
            "venue": "Am J Respir Crit Care Med",
            "volume": "171",
            "issn": "",
            "pages": "912-930",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "The use of induced sputum to investigate airway inflammation",
            "authors": [],
            "year": 1997,
            "venue": "Thorax",
            "volume": "52",
            "issn": "",
            "pages": "498-501",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Inflammatory subtypes in asthma: assessment and identification using induced sputum",
            "authors": [],
            "year": 2006,
            "venue": "Respirology.",
            "volume": "11",
            "issn": "",
            "pages": "54-61",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Development and validation of a questionnaire to measure asthma control",
            "authors": [],
            "year": 1999,
            "venue": "Eur Respir J",
            "volume": "14",
            "issn": "",
            "pages": "902-907",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF27": {
            "title": "An economical tandem multiplex real\u2010time PCR technique for the detection of a comprehensive range of respiratory pathogens",
            "authors": [],
            "year": 2009,
            "venue": "Viruses",
            "volume": "1",
            "issn": "",
            "pages": "42-56",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF28": {
            "title": "Respiratory viral pathogens associated with lower respiratory tract disease among young children in the highlands of Papua New Guinea",
            "authors": [],
            "year": 2012,
            "venue": "J Clin Virol",
            "volume": "54",
            "issn": "",
            "pages": "235-239",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF29": {
            "title": "A diverse group of previously unrecognized human rhinoviruses are common causes of respiratory illnesses in infants",
            "authors": [],
            "year": 2007,
            "venue": "PLoS One",
            "volume": "2",
            "issn": "",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF30": {
            "title": "Improved molecular typing assay for rhinovirus species A, B, and C. Journal of Clinical Microbiology. American Society for",
            "authors": [],
            "year": 2014,
            "venue": "Microbiology",
            "volume": "52",
            "issn": "",
            "pages": "2461-2471",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF31": {
            "title": "Mepolizumab treatment in patients with severe eosinophilic asthma",
            "authors": [],
            "year": 2014,
            "venue": "N Engl J Med",
            "volume": "371",
            "issn": "",
            "pages": "1198-1207",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF32": {
            "title": "Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double\u2010blind, placebo\u2010controlled trial",
            "authors": [],
            "year": 2012,
            "venue": "Lancet",
            "volume": "380",
            "issn": "",
            "pages": "651-659",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF33": {
            "title": "Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12\u2010month follow\u2010up analysis",
            "authors": [],
            "year": 2014,
            "venue": "J Allergy Clin Immunol",
            "volume": "133",
            "issn": "",
            "pages": "921-923",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF34": {
            "title": "Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children",
            "authors": [],
            "year": 2006,
            "venue": "Thorax",
            "volume": "61",
            "issn": "",
            "pages": "376-382",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF35": {
            "title": "Innate immune responses to rhinovirus are reduced by the high\u2010affinity IgE receptor in allergic asthmatic children",
            "authors": [],
            "year": 2012,
            "venue": "J Allergy Clin Immunol",
            "volume": "130",
            "issn": "",
            "pages": "489-495",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF36": {
            "title": "Rhinovirus 16\u2010induced IFN\u2010&alpha; and IFN\u2010&beta; are deficient in bronchoalveolar lavage cells in asthmatic patients",
            "authors": [],
            "year": 2012,
            "venue": "J Allergy Clin Immunol.",
            "volume": "129",
            "issn": "",
            "pages": "1506-1514",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF37": {
            "title": "Rhinovirus\u2010induced PBMC responses and outcome of experimental infection in allergic subjects",
            "authors": [],
            "year": 2000,
            "venue": "J Allergy Clin Immunol",
            "volume": "105",
            "issn": "",
            "pages": "692-698",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF38": {
            "title": "Role of deficient type III interferon\u2010\u03bb production in asthma exacerbations",
            "authors": [],
            "year": 2006,
            "venue": "Nat Med",
            "volume": "12",
            "issn": "",
            "pages": "1023-1026",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF39": {
            "title": "Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection",
            "authors": [],
            "year": 2000,
            "venue": "Am J Respir Crit Care Med",
            "volume": "162",
            "issn": "",
            "pages": "2226-2231",
            "other_ids": {
                "DOI": []
            }
        }
    }
}